You have read all your free articles, to continue reading subscribe to read the rest of this content.
Active Biotech has announced that its partner Teva Pharmaceutical Industries Ltd. will initiate a phase II clinical trial to evaluate the efficacy and safety of oral laquinimod for the treatment of Huntington's disease. Teva started a global research collaboration in the summer of 2013 to develoAlready a subscriber Login You have…
Novo Nordisk has announced that Victoza (liraglutide) significantly reduced the risk of the composite primary endpoint of cardiovascular (CV) death, non-fatal myocardial infarction (heart attack) or non-fatal stroke by 13% vs placebo (95% confidence interval [CI]: 0.78; 0.97, p=0.01), when added to Already a subscriber Login You have read all…
Follicum has announced that the company has signed a collaboration agreement with proDERM for conducting the new clinical trial with a cream-like formulation of FOL-005 to be tested on alopecia patients (patients with hair loss). The company expects to be ready for starting the clinical trial shoAlready a subscriber Login…
Finnish Biotie announces start of tozadenant Phase 3 Study of tozadenant, an investigational adenosine A2a receptor antagonist, in patients with Parkinson's disease experiencing levodopa related end-of-dose "wearing-off". The Phase 3 study (TOZ-PD) is a randomized, double-blind, placebo controlledAlready a subscriber Login You have read all your free articles, to continue…
